← Back to Patent Explorer
US4684727A Expired / Lapsed US ⏱️ 0.0 years remaining

Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents

Assignee: Merck Sharp & Dohme LLC
•
Filing: 1985-07-29
•
Granted: 1987-08-04
•
Expires: 2005-07-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Zwitterionic bicyclic compounds are disclosed which are useful as anti-allergic, anti-inflammatory and/or cytoprotective agents. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.

Inventors

  • 👤 David J. Blythin
  • 👤 Ho-Jane Shue

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 20:25
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; A61P; A61P1/00; A61P1/04; A61P29/00; A61P37/00; A61P37/02; A61P37/06; A61P37/08; C07D215/00; C07D215/02; C07D215/16; C07D215/36; C07D453/00; C07D453/02

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 751 words
A compound having the structural formula I ##STR9## and pharmaceutically acceptable salts thereof, wherein: X represents --N═ and W represents --CH═ or --N═; Z 1 and Z 2 are the same or different and each independently represents --O-- or --S--; R 1 , R 2 , R 3 , R 4 and R 5 are the same or different and each may be independently selected from the group consisting of H, alkyl having from 1 to 12 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynyl having from 3 to 8 carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in the alkoxy portion and from 2 to 6 atoms in the alkyl portion thereof, hydroxyalkyl having from 2 to 8 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, acyloxyalkyl having from 1 to 6 carbon atoms in the acyloxy portion and from 2 to 8 carbon atoms in teh alkyl portion thereof, and --R 6 --CO 2 R 0 wherein R 6 represents an alkylene group having from 1 to 6 carbon atoms and R 0 represents hydrogen or an alkyl group having from 1 to 6 carbon atoms, with the provisos that the OH of the hydroxyalkyl group and the acyloxy of the acyloxyalkyl group are not joined to the same carbon atom as another heteroatom and that, when R 1 , R 2 and/or R 3 are alkenyl or alkynyl, there is at least one carbon-carbon single bond between the nitrogen atom and the carbon-carbon double or triple bond; in addition, one of R 1 , R 2 or R 3 can be an aryl group which contains 6 to 15 atoms or an aromatic heterocyclic group which contains 4 to 14 carbon atoms, either of which can be substituted with one to three substituents Y asa defined below; in further addition, two of R 1 , R 2 and R 3 can be joined together to represent an imdazolyl ring or to represent a ring which can contain from 2 to 8 carbon atoms, said ring optionally containing a --O--, --S-- and/or --NR 4 -- heteroatomic group (wherein R 4 is as defined above ) and/or optionally containing a carbon-carbon double bond, and said ring optionally being substituted with one to three additional substituents R 7 which substituents may be the same or different and are each independently selected from OH with the proviso that OH is not on a carbon already joined to a hereto atom, --O-- acyl having from 1 to 6 atoms; hydroxyalkyl having from 1 to 8 carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in each alkyl portion thereof, alkyl having from 1 to 6 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynyl having from 3 to 8 carbon atoms, or any two R 7 substituent groups may represent a hydrocarbon ring having from 4 to 8 total carbon atoms; in still further addition, all three of R 1 , R 2 and R 3 can be joined together to represent a polycyclic ring, which polycyclic ring can optionally be substituted by one to three substituents groups R 7 as defined above; m is an integer of from 0 to 3; n is an integer of from 0 to 2; Q represents an aryl or an aromatic heterocyclic group which can optionally be substituted with 1 to 3 substituents Y as defined below; each Y substituent is independently selected from the group consisting of hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, NO 2 , alkoxy having from 1 to 6 carbon atoms, trifluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, hydroxyalkyl having from 1 to 6 carbon atoms, --S(O) n --R 8 (wherein R 8 represents alkyl having from 1 to 6 carbon atoms and n is as defined above ), --SO 2 NH 2 , --CO--R 9 (wherein R 9 represents OH, --NH--R 8 or --O--R 8 , where R 8 is as defined above), --O--B--COR 9 (wherein B represents an alkylene group having from 1 to 4 carbon atoms and R 9 is as defined above ), --NH 2 , --NHCHO, --NH--CO--R.sup. 9 (wherein R 9 is as defined above, with the proviso that it is not hydroxy), --NH--COCF 3 , --NH--SO 2 R 8 (wherein R 8 is as defined above ), and --NHSO 2 CF 3 .
Claim 2
Dependent Claim 751 words
A compound having the structural formula I ##STR9## and pharmaceutically acceptable salts thereof, wherein: X represents --N═ and W represents --CH═ or --N═; Z 1 and Z 2 are the same or different and each independently represents --O-- or --S--; R 1 , R 2 , R 3 , R 4 and R 5 are the same or different and each may be independently selected from the group consisting of H, alkyl having from 1 to 12 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynyl having from 3 to 8 carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in the alkoxy portion and from 2 to 6 atoms in the alkyl portion thereof, hydroxyalkyl having from 2 to 8 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, acyloxyalkyl having from 1 to 6 carbon atoms in the acyloxy portion and from 2 to 8 carbon atoms in teh alkyl portion thereof, and --R 6 --CO 2 R 0 wherein R 6 represents an alkylene group having from 1 to 6 carbon atoms and R 0 represents hydrogen or an alkyl group having from 1 to 6 carbon atoms, with the provisos that the OH of the hydroxyalkyl group and the acyloxy of the acyloxyalkyl group are not joined to the same carbon atom as another heteroatom and that, when R 1 , R 2 and/or R 3 are alkenyl or alkynyl, there is at least one carbon-carbon single bond between the nitrogen atom and the carbon-carbon double or triple bond; in addition, one of R 1 , R 2 or R 3 can be an aryl group which contains 6 to 15 atoms or an aromatic heterocyclic group which contains 4 to 14 carbon atoms, either of which can be substituted with one to three substituents Y asa defined below; in further addition, two of R 1 , R 2 and R 3 can be joined together to represent an imdazolyl ring or to represent a ring which can contain from 2 to 8 carbon atoms, said ring optionally containing a --O--, --S-- and/or --NR 4 -- heteroatomic group (wherein R 4 is as defined above ) and/or optionally containing a carbon-carbon double bond, and said ring optionally being substituted with one to three additional substituents R 7 which substituents may be the same or different and are each independently selected from OH with the proviso that OH is not on a carbon already joined to a hereto atom, --O-- acyl having from 1 to 6 atoms; hydroxyalkyl having from 1 to 8 carbon atoms, alkoxyalkyl having from 1 to 6 carbon atoms in each alkyl portion thereof, alkyl having from 1 to 6 carbon atoms, alkenyl having from 3 to 8 carbon atoms, alkynyl having from 3 to 8 carbon atoms, or any two R 7 substituent groups may represent a hydrocarbon ring having from 4 to 8 total carbon atoms; in still further addition, all three of R 1 , R 2 and R 3 can be joined together to represent a polycyclic ring, which polycyclic ring can optionally be substituted by one to three substituents groups R 7 as defined above; m is an integer of from 0 to 3; n is an integer of from 0 to 2; Q represents an aryl or an aromatic heterocyclic group which can optionally be substituted with 1 to 3 substituents Y as defined below; each Y substituent is independently selected from the group consisting of hydroxy, alkyl having from 1 to 6 carbon atoms, halogen, NO 2 , alkoxy having from 1 to 6 carbon atoms, trifluoromethyl, cyano, cycloalkyl having from 3 to 7 carbon atoms, alkenyloxy having from 3 to 6 carbon atoms, alkynyloxy having from 3 to 6 carbon atoms, hydroxyalkyl having from 1 to 6 carbon atoms, --S(O) n --R 8 (wherein R 8 represents alkyl having from 1 to 6 carbon atoms and n is as defined above ), --SO 2 NH 2 , --CO--R 9 (wherein R 9 represents OH, --NH--R 8 or --O--R 8 , where R 8 is as defined above), --O--B--COR 9 (wherein B represents an alkylene group having from 1 to 4 carbon atoms and R 9 is as defined above ), --NH 2 , --NHCHO, --NH--CO--R.sup. 9 (wherein R 9 is as defined above, with the proviso that it is not hydroxy), --NH--COCF 3 , --NH--SO 2 R 8 (wherein R 8 is as defined above ), and --NHSO 2 CF 3 .
Claim 3
Dependent Claim 14 words
A compound according to claim 1, wherein X is --N═ and W is --CH═.
Claim 4
Dependent Claim 18 words
A compound according to claim 2, wherein at least one of Z 1 and Z 2 is O.
Claim 5
Dependent Claim 15 words
A compound according to claim 2, wherein Z 1 and Z 2 both are O.
Claim 6
Dependent Claim 10 words
A compound according to claim 3, wherein n is 0.
Claim 7
Dependent Claim 10 words
A compound according to claim 5, wherein m is 0.
Claim 8
Dependent Claim 23 words
A compound according to claim 6, wherein Q is an aryl group, which may optionally be substituted with one to three Y groups.
Claim 9
Dependent Claim 23 words
A compound according to claim 7, wherein Q is an aryl group, which may optionally be substituted with one or two Y groups.
Claim 10
Dependent Claim 39 words
A compound selected from: 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-4-hydroxy-piperidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthridin-3-yl)quinuclidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthridin-3-yl)-1-methyl-morpholinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)piperidinium hydroxide, inner salt; or 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-2-hydroxymethyl-piperidinium hydroxide, inner salt; or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim 39 words
A compound selected from: 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-4-hydroxy-piperidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthridin-3-yl)quinuclidinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthridin-3-yl)-1-methyl-morpholinium hydroxide, inner salt; 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)piperidinium hydroxide, inner salt; or 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-2-hydroxymethyl-piperidinium hydroxide, inner salt; or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim 14 words
A compound having the name 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidinium hydroxide, inner salt and pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim 14 words
A compound having the name 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-naphthyridin-3-yl)-1-methyl-pyrrolidinium hydroxide, inner salt and pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim 15 words
A compound having the same 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-napthyridin-3-yl)pyrrolidinium hydoxide, inner salt or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim 15 words
A compound having the same 1-(1,2-dihydro-4-hydroxy-1-phenyl-2-oxo-1,8-napthyridin-3-yl)pyrrolidinium hydoxide, inner salt or a pharmaceutically acceptable salt thereof.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-08-03 1991-02-02 1991-08-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-08-03 1995-02-02 1995-08-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-08-03 1999-02-02 1999-08-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag